乳腺疾病专题论著
ENGLISH ABSTRACT
残余肿瘤负荷评估乳腺癌新辅助治疗疗效的影响因素及其预后价值(附视频导读)
鞠仙莉
阎红琳
柯晓康
管枫
黄奥玲
袁静萍
作者及单位信息
·
DOI: 10.3760/cma.j.cn.115807-20230427-00127
Factors influencing the efficacy of neoadjuvant therapy in breast cancer assessed by RCB as well as the prognostic value of RCB in neoadjuvant therapy (with video)
Ju Xianli
Yan Honglin
Ke Xiaokang
Guan Feng
Huang Aoling
Yuan Jingping
Authors Info & Affiliations
Ju Xianli
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Yan Honglin
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Ke Xiaokang
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Guan Feng
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Huang Aoling
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Yuan Jingping
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
·
DOI: 10.3760/cma.j.cn.115807-20230427-00127
624
66
0
0
1
0
PDF下载
APP内阅读
摘要

目的采用残余肿瘤负荷(residual cancer burden,RCB)评估系统分析乳腺癌新辅助治疗疗效的影响因素,并探讨RCB评估在新辅助治疗中的预后价值。

方法收集武汉大学人民医院2019年11月至2022年11月364例行新辅助治疗的乳腺癌患者的临床病理资料及术后RCB分级,采用 χ 2 检验分析RCB分级与临床病理参数的关系,Spearman相关性分析法分析RCB分级与临床病理特征的相关性,Logistic回归分析病理完全缓解(pathologic complete response,pCR)的影响因素,Kaplan-Meier生存分析和log-rank检验方法评估累积生存期。

结果364例经新辅助治疗患者中,术后获得RCB 0级者129例、RCB Ⅰ级46例、RCB Ⅱ级109例、RCB Ⅲ级80例。新辅助治疗前患者的组织学分级( χ 2 =21.757, P=0.000)、雌激素受体(estrogen receptor,ER)( χ 2 =52.837, P=0.000)、孕激素受体(progesterone receptor,PR)( χ 2 =55.658, P=0.000)、人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)( χ 2 =89.040, P=0.000)的表达情况,Ki67表达( χ 2 =12.927, P=0.005),分子分型( χ 2 =80.793, P=0.000)及术前淋巴结状态( χ 2 =25.764, P=0.000)均显示与患者术后的RCB分级相关;进一步相关性分析显示组织学分级( r=-0.229, P=0.000)、HER2表达情况( r=-0.465, P=0.000)及Ki67表达量( r=-0.179, P=0.000)与RCB分级呈负相关,而ER( r=0.352, P=0.000)、PR( r=0.379, P=0.000)及淋巴结转移情况( r=0.214, P=0.000)与RCB分级呈正相关。Logistic回归分析显示患者术前高组织学分级,ER、PR、AR阴性表达,HER2阳性表达,Ki67高增殖指数,淋巴结未发生转移是术后获得pCR的有利因素,且PR、AR、HER2是术后获得pCR的独立预测因素。Kaplan-Meier生存分析显示不同RCB分级患者术后的累积生存期差异有统计学意义( P=0.004)。

结论乳腺癌的术后RCB分级与其新辅助治疗前诸多临床病理特征及生存预后密切相关,与RCB分级密切相关的临床病理因素同时也是影响新辅助治疗pCR的重要影响因素,故RCB分级有较高的预后预测价值。

乳腺癌;新辅助治疗;残余肿瘤负荷;病理完全缓解
ABSTRACT

ObjectiveThe residual cancer burden (RCB) evaluation system was used to analyze the influencing factors of the efficacy of neoadjuvant therapy in breast cancer, and to explore the prognostic value of RCB evaluation in neoadjuvant therapy.

MethodsClinicopathologic data and postoperative RCB grading of 364 breast cancer patients who underwent neoadjuvant therapy in Renmin Hospital of Wuhan University from Nov. 2019 to Nov. 2022 were collected. Chi-square test was used to analyze the relationship between RCB grading and clinicopathological parameters, and Spearman’s rank correlation analysis was performed to evaluate the correlation between RCB grading and clinicopathological characteristics. Factors influencing pathologic complete response (pCR) were analyzed by Logistic regression. Kaplan-Meier survival analysis and log-rank test were used to evaluate cumulative survival.

ResultsAmong the 364 patients who underwent neoadjuvant therapy, 129 cases of RCB grade 0 and 235 cases of RCB gradeⅠ-Ⅲ (including 46 cases of RCB gradeⅠ, 109 cases of RCB grade Ⅱ and 80 cases of RCB grade Ⅲ) were obtained after surgery. Histological classification ( χ 2 =21.757, P=0.000), estrogen receptor (ER) ( χ 2 =52.837, P=0.000), progesterone receptor (PR) ( χ 2 =55.658, P=0.000), human epidermal growth factor receptor-2 (HER2) ( χ 2=89.040, P=0.000), Ki67 expression ( χ 2=12.927, P=0.005), molecular typing ( χ 2 =80.793, P=0.000) and preoperative lymph node status ( χ 2 =25.764, P=0.000) were all associated with postoperative RCB grading. Further correlation analysis showed that histological grade ( r=-0.229, P=0.000), HER2 expression ( r=-0.465, P=0.000) and Ki67 expression ( r=-0.179, P=0.000) were negatively correlated with RCB grading, while ER ( r=0.352, P=0.000), PR ( r=0.379, P=0.000) and lymph node metastasis ( r=0.214, P=0.000) were positively correlated with RCB grading. Logistic regression analysis showed that high histological grade, negative expression of ER, PR and AR, positive expression of HER2, high proliferation index of Ki67 and no lymph node metastasis were favorable factors for postoperative pCR, and PR, AR and HER2 were independent predictors of postoperative pCR. Kaplan-Meier survival analysis showed significant differences in postoperative cumulative survival among patients with different RCB grades ( P=0.004) .

ConclusionsPostoperative RCB grading of breast cancer is closely related to many clinicopathological features before neoadjuvant therapy and survival prognosis. Clinicopathological factors closely related to RCB grading are also important influencing factors affecting the pCR of patients with neoadjuvant therapy. Therefors, RCB grading has a high prognostic value.

Breast cancer;Neoadjuvant therapy;Residual cancer burden;Pathologic complete response
Yuan Jingping, Email: mocdef.nabuyila3002gnipgnijnauy
引用本文

鞠仙莉,阎红琳,柯晓康,等. 残余肿瘤负荷评估乳腺癌新辅助治疗疗效的影响因素及其预后价值(附视频导读)[J]. 中华内分泌外科杂志,2023,17(05):518-523.

DOI:10.3760/cma.j.cn.115807-20230427-00127

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
视频暂时无法播放,请稍后刷新重试 #007.4
00:00
00:00 / 03:03
弹幕
vr模式
高清
流畅
自动
2x
1.5x
1.2x
1x
0.5x
字幕
模式
视频音频
线路
vr模式
裸眼眼镜
播放器
FlashHTML5
画中画
网页全屏
全屏
Version:v1.60.2
视频导读
乳腺癌已成为全球发病率最高的恶性肿瘤之一,对女性的健康产生巨大影响 [ 1 ]。近年来,术前新辅助治疗(neoadjuvant therapy,NAT)方法的应用越来越广,其通过降低肿瘤分期允许更小范围的乳腺和腋窝手术,使得局部晚期不能手术的患者获得手术机会。但不同患者对NAT的疗效不一,仍有一部分患者在化疗后发生疾病进展,研究显示这可能与乳腺癌的分子分型、激素受体表达情况及术前淋巴结转移情况等相关。目前已有多项研究表明上述分子学特征与Miller/Payne分级(MP分级)及残余肿瘤负荷(residual cancer burden,RCB)评估系统相关,且与预后情况密切相关 [ 2 , 3 ]。MP分级系统已广泛应用于乳腺癌患者NAT后疗效的预测,但目前对术后大体标本检测的RCB分级研究尚少,且大部分为国外样本的数据。本研究通过采用RCB评估系统分析乳腺癌新辅助治疗疗效的影响因素,并探讨RCB评估在新辅助治疗中的预后价值。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Sung H , Ferlay J , Siege RL ,et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,713):209-249. DOI: 10.3322/caac.21660 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Wang L , Luo R , Lu Q ,et al. Miller-payne grading and 70-gene signature are associated with prognosis of hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer after neoadjuvant chemotherapy[J]. Front Oncol, 2021,11:735670. DOI: 10.3389/fonc.2021.735670 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Marieke VDN , Sonal S , Jane W ,et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients[J]. Lancet Oncol, 2022,23:149-160. DOI: 10.1016/S1470-2045(21)00589-1 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Senkus E , Kyriakides S , Ohno S ,et al. Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up[J]. Ann Oncol, 2015,265):8-30. DOI: 10.1093/annonc/mdv298 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019,298):609-680. DOI: 10.19401/j.cnki.1007-3639.2019.08.009 .
返回引文位置Google Scholar
百度学术
万方数据
Breast Cancer Professional Committee of Chinese Anti-Cancer Association. Guidelines and Norms for Diagnosis and Treatment of Breast Cancer of Chinese Anticancer Association(2019 Edition)[J]. China Oncology, 2019,298):609-680. DOI: 10.19401/j.cnki.1007-3639.2019.08.009 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[6]
中国乳腺癌新辅助治疗专家组. 中国乳腺癌新辅助治疗专家共识(2019年版)[J]. 中国癌症杂志, 2019,295):390-400. DOI: 10.19401/j.cnki.1007-3639.2019.05.009 .
返回引文位置Google Scholar
百度学术
万方数据
China Breast Cancer Neoadjuvant Therapy Expert Group. Chinese Expert Consensus on Neoadjuvant Therapy for Breast Cancer(2019 Edition)[J]. China Oncology, 2019,295):390-400. DOI: 10.19401/j.cnki.1007-3639.2019.05.009 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[7]
Li XB , Krishnamurti U , Bhattarai S ,et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer[J]. Am J Clin Pathol, 2016,1456):871-878. DOI: 10.1093/ajcp/aqw045 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
侯巍,姚倩,钮东峰,. 乳腺癌新辅助治疗Miller-Payne分级相关临床病理特征分析及预测模型建立[J]. 中华病理学杂志, 2022,518):743-748. DOI: 10.3760/cma.j.cn112151-20220413-00277 .
返回引文位置Google Scholar
百度学术
万方数据
Hou W , Yao Q , Niu DF ,et al. Clinicopathological characteristics related to Miller/Payne grading system of breast carcinoma after neoadjuvant therapy and establishment of novel prediction models[J]. Chin J Pathol, 202,518):743-748. DOI: 10.3760/cma.j.cn112151-20220413-00277 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[9]
詹勇涛. 乳腺癌新辅助化疗患者预后评估指标的初步探讨[D]. 广州医科大学, 2018. DOI: 10.7666/d.D01553141 .
返回引文位置Google Scholar
百度学术
万方数据
Zhan YT . Preliminary study on prognosis evaluation indexes of patients with neoadjuvant chemotherapy for breast cancer[D]. Guangzhou Medical University, 2018. DOI: 10.7666/d.D01553141 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[10]
Kong X , Moran MS , Zhang N ,et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients[J]. Eur J Cancer, 2011,4714):2084-2090. DOI: 10.1016/j.ejca.2011.06.014 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
练斌,洪朝寅,余锦婕,. 广西地区不同分子分型乳腺癌的临床病理特征及预后研究[J]. 实用医学杂志, 2021,3722):2928-2933. DOI: 10.3969/j.issn.1006-5725.2021.22.020 .
返回引文位置Google Scholar
百度学术
万方数据
Lian B , Hong CY , Yu JJ ,et al. Clinicopathological features and prognosis of different molecular types of breast cancer in Guangxi[J]. The Journal of Practical Medicine, 2021,3722):2928-2933. DOI: 10.3969/j.issn.1006-5725.2021.22.020 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
备注信息
A
袁静萍,Email: mocdef.nabuyila3002gnipgnijnauy
B

鞠仙莉:实施研究、统计学分析、论文撰写;阎红琳、柯晓康、管枫、黄奥玲:论文修改、技术支持;袁静萍:研究指导、论文修改

C
所有作者均声明不存在利益冲突
D
湖北省卫生健康科研基金资助 (WJ2021M151)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号